Cargando…

Real-World Outcomes of Adalimumab Treatment for Moderate and Severe Psoriasis in Korean Patients (RAPSODI Study)

BACKGROUND: Psoriasis imposes a significant treatment burden on patients, particularly impacting well-being and quality of life (QoL). The psychosocial impact of psoriasis treatments remains unexplored in most patient populations. OBJECTIVE: To assess the impact of adalimumab on health-related QoL (...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Dong Hyun, Son, Sang Wook, Jeong, Ki-Heon, Ahn, Jiyoung, Lee, Eun-So, Kim, Il-Hwan, Lee, Un Ha, Park, Hai-Jin, Ko, Joo Yeon, Kim, Byung-Soo, Kim, Jin Ju, Rashid, Javed, Kim, Kwang Joong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Dermatological Association; The Korean Society for Investigative Dermatology 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10112372/
https://www.ncbi.nlm.nih.gov/pubmed/37041704
http://dx.doi.org/10.5021/ad.22.041
_version_ 1785027612878307328
author Kim, Dong Hyun
Son, Sang Wook
Jeong, Ki-Heon
Ahn, Jiyoung
Lee, Eun-So
Kim, Il-Hwan
Lee, Un Ha
Park, Hai-Jin
Ko, Joo Yeon
Kim, Byung-Soo
Kim, Jin Ju
Rashid, Javed
Kim, Kwang Joong
author_facet Kim, Dong Hyun
Son, Sang Wook
Jeong, Ki-Heon
Ahn, Jiyoung
Lee, Eun-So
Kim, Il-Hwan
Lee, Un Ha
Park, Hai-Jin
Ko, Joo Yeon
Kim, Byung-Soo
Kim, Jin Ju
Rashid, Javed
Kim, Kwang Joong
author_sort Kim, Dong Hyun
collection PubMed
description BACKGROUND: Psoriasis imposes a significant treatment burden on patients, particularly impacting well-being and quality of life (QoL). The psychosocial impact of psoriasis treatments remains unexplored in most patient populations. OBJECTIVE: To assess the impact of adalimumab on health-related QoL (HRQoL) in Korean patients with psoriasis. METHODS: This 24-week, multicenter, observational study, assessed HRQoL in Korean patients treated with adalimumab in a real-world setting. Patient-reported outcomes (PROs) including European Quality of Life-5 Dimension scale (EQ-5D), EQ-5D VAS, SF-36, and DLQI were evaluated at week 16 and 24, versus baseline. Patient satisfaction was assessed using TSQM. RESULTS: Among 97 enrolled patients, 77 were assessed for treatment effectiveness. Most patients were male (52, 67.5%) and mean age was 45.4 years. Median baseline body surface area and Psoriasis Area and Severity Index (PASI) scores were 15.00 (range 4.00~80.00) and 12.40 (range 2.70~39.40), respectively. Statistically significant improvements in all PROs were observed between baseline and week 24. Mean EQ-5D score improved from 0.88 (standard deviation [SD], 0.14) at baseline to 0.91 (SD, 0.17) at week 24 (p=0.0067). The number of patients with changes in PASI 75, 90, or 100 from baseline to week 16 and 24 were 65 (84.4%), 17 (22.1%), and 1 (1.3%); and 64 (83.1%), 21 (27.3%), and 2 (2.6%), respectively. Overall treatment satisfaction was reported, including effectiveness and convenience. No unexpected safety findings were noted. CONCLUSION: Adalimumab improved QoL and was well-tolerated in Korean patients with moderate to severe psoriasis, as demonstrated in a real-world setting. Clinical trial registration number (clinicaltrials.gov: NCT03099083).
format Online
Article
Text
id pubmed-10112372
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher The Korean Dermatological Association; The Korean Society for Investigative Dermatology
record_format MEDLINE/PubMed
spelling pubmed-101123722023-04-19 Real-World Outcomes of Adalimumab Treatment for Moderate and Severe Psoriasis in Korean Patients (RAPSODI Study) Kim, Dong Hyun Son, Sang Wook Jeong, Ki-Heon Ahn, Jiyoung Lee, Eun-So Kim, Il-Hwan Lee, Un Ha Park, Hai-Jin Ko, Joo Yeon Kim, Byung-Soo Kim, Jin Ju Rashid, Javed Kim, Kwang Joong Ann Dermatol Original Article BACKGROUND: Psoriasis imposes a significant treatment burden on patients, particularly impacting well-being and quality of life (QoL). The psychosocial impact of psoriasis treatments remains unexplored in most patient populations. OBJECTIVE: To assess the impact of adalimumab on health-related QoL (HRQoL) in Korean patients with psoriasis. METHODS: This 24-week, multicenter, observational study, assessed HRQoL in Korean patients treated with adalimumab in a real-world setting. Patient-reported outcomes (PROs) including European Quality of Life-5 Dimension scale (EQ-5D), EQ-5D VAS, SF-36, and DLQI were evaluated at week 16 and 24, versus baseline. Patient satisfaction was assessed using TSQM. RESULTS: Among 97 enrolled patients, 77 were assessed for treatment effectiveness. Most patients were male (52, 67.5%) and mean age was 45.4 years. Median baseline body surface area and Psoriasis Area and Severity Index (PASI) scores were 15.00 (range 4.00~80.00) and 12.40 (range 2.70~39.40), respectively. Statistically significant improvements in all PROs were observed between baseline and week 24. Mean EQ-5D score improved from 0.88 (standard deviation [SD], 0.14) at baseline to 0.91 (SD, 0.17) at week 24 (p=0.0067). The number of patients with changes in PASI 75, 90, or 100 from baseline to week 16 and 24 were 65 (84.4%), 17 (22.1%), and 1 (1.3%); and 64 (83.1%), 21 (27.3%), and 2 (2.6%), respectively. Overall treatment satisfaction was reported, including effectiveness and convenience. No unexpected safety findings were noted. CONCLUSION: Adalimumab improved QoL and was well-tolerated in Korean patients with moderate to severe psoriasis, as demonstrated in a real-world setting. Clinical trial registration number (clinicaltrials.gov: NCT03099083). The Korean Dermatological Association; The Korean Society for Investigative Dermatology 2023-04 2023-03-09 /pmc/articles/PMC10112372/ /pubmed/37041704 http://dx.doi.org/10.5021/ad.22.041 Text en Copyright © The Korean Dermatological Association and The Korean Society for Investigative Dermatology https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0 (https://creativecommons.org/licenses/by-nc/4.0/) ) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Kim, Dong Hyun
Son, Sang Wook
Jeong, Ki-Heon
Ahn, Jiyoung
Lee, Eun-So
Kim, Il-Hwan
Lee, Un Ha
Park, Hai-Jin
Ko, Joo Yeon
Kim, Byung-Soo
Kim, Jin Ju
Rashid, Javed
Kim, Kwang Joong
Real-World Outcomes of Adalimumab Treatment for Moderate and Severe Psoriasis in Korean Patients (RAPSODI Study)
title Real-World Outcomes of Adalimumab Treatment for Moderate and Severe Psoriasis in Korean Patients (RAPSODI Study)
title_full Real-World Outcomes of Adalimumab Treatment for Moderate and Severe Psoriasis in Korean Patients (RAPSODI Study)
title_fullStr Real-World Outcomes of Adalimumab Treatment for Moderate and Severe Psoriasis in Korean Patients (RAPSODI Study)
title_full_unstemmed Real-World Outcomes of Adalimumab Treatment for Moderate and Severe Psoriasis in Korean Patients (RAPSODI Study)
title_short Real-World Outcomes of Adalimumab Treatment for Moderate and Severe Psoriasis in Korean Patients (RAPSODI Study)
title_sort real-world outcomes of adalimumab treatment for moderate and severe psoriasis in korean patients (rapsodi study)
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10112372/
https://www.ncbi.nlm.nih.gov/pubmed/37041704
http://dx.doi.org/10.5021/ad.22.041
work_keys_str_mv AT kimdonghyun realworldoutcomesofadalimumabtreatmentformoderateandseverepsoriasisinkoreanpatientsrapsodistudy
AT sonsangwook realworldoutcomesofadalimumabtreatmentformoderateandseverepsoriasisinkoreanpatientsrapsodistudy
AT jeongkiheon realworldoutcomesofadalimumabtreatmentformoderateandseverepsoriasisinkoreanpatientsrapsodistudy
AT ahnjiyoung realworldoutcomesofadalimumabtreatmentformoderateandseverepsoriasisinkoreanpatientsrapsodistudy
AT leeeunso realworldoutcomesofadalimumabtreatmentformoderateandseverepsoriasisinkoreanpatientsrapsodistudy
AT kimilhwan realworldoutcomesofadalimumabtreatmentformoderateandseverepsoriasisinkoreanpatientsrapsodistudy
AT leeunha realworldoutcomesofadalimumabtreatmentformoderateandseverepsoriasisinkoreanpatientsrapsodistudy
AT parkhaijin realworldoutcomesofadalimumabtreatmentformoderateandseverepsoriasisinkoreanpatientsrapsodistudy
AT kojooyeon realworldoutcomesofadalimumabtreatmentformoderateandseverepsoriasisinkoreanpatientsrapsodistudy
AT kimbyungsoo realworldoutcomesofadalimumabtreatmentformoderateandseverepsoriasisinkoreanpatientsrapsodistudy
AT kimjinju realworldoutcomesofadalimumabtreatmentformoderateandseverepsoriasisinkoreanpatientsrapsodistudy
AT rashidjaved realworldoutcomesofadalimumabtreatmentformoderateandseverepsoriasisinkoreanpatientsrapsodistudy
AT kimkwangjoong realworldoutcomesofadalimumabtreatmentformoderateandseverepsoriasisinkoreanpatientsrapsodistudy